Healthy Inc > Blog > ACT antimalarial manufacturer
Posted on:

What is the use of artesunate sulfadoxine pyrimethamine tablet?

In the pharmaceutical industry, the combination of Artesunate and Sulfadoxine-Pyrimethamine (AS+SP) is a powerful Artemisinin-based Combination Therapy (ACT). As a pharmacist, I characterize this fixed-dose combination (FDC) as a strategic multi-target treatment designed to clear parasites rapidly while providing a long-acting “chemical umbrella” to prevent the recurrence of infection.

Primary Clinical Uses

  • Treatment of Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum in areas where the parasite remains sensitive to the SP component.

  • Rapid Parasite Clearance: The Artesunate component ensures that the parasite load in the blood is reduced within hours, preventing the onset of severe malaria.

  • Prevention of Recrudescence: The long-acting Sulfadoxine and Pyrimethamine components remain in the bloodstream for weeks to kill any residual parasites.

  • Intermittent Preventive Treatment (IPT): In specific high-risk regions, this combination is sometimes utilized in pregnancy (IPTp) or for infants (IPTi) to reduce the burden of malaria.

Mechanism of Action

This combination employs a dual-mechanism approach to ensure parasitic death:

Artesunate (Fast-Acting): Generates reactive free radicals that damage the parasite’s proteins and membranes by reacting with the iron in the parasite’s food vacuole. It targets the asexual erythrocytic stages.

Sulfadoxine & Pyrimethamine (Long-Acting): These act as sequential inhibitors of folic acid synthesis. Sulfadoxine inhibits the enzyme dihydropteroate synthase, while Pyrimethamine inhibits dihydrofolate reductase. Since parasites must synthesize their own folates for DNA production, this blockade effectively halts their replication.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, AS+SP is a specialized product requiring high-tier regulatory compliance:

  • Stability Management: Artesunate is highly sensitive to moisture and heat. As a WHO-GMP manufacturer, we utilize Alu-Alu blister packaging and low-humidity manufacturing zones to protect the integrity of the Artesunate API during storage and transit.

  • Fixed-Dose Precision: We ensure that the ratio of Sulfadoxine to Pyrimethamine is precisely 20:1 (typically 500 mg/25 mg) to maintain the synergistic effect while minimizing potential side effects.

  • Global Export Niche: This combination is a staple for B2B distributors and government health tenders in sub-Saharan Africa and Southeast Asia. Our Mumbai hub is optimized for high-capacity production to meet international public health demands.

  • Regulatory Dossiers: We provide comprehensive CTD/eCTD documentation and stability data for Zone IVb to facilitate smooth registration in malaria-endemic international markets.

Artesunate Sulphadoxine Pyrimethamine Tablets

Posted on:

What is the use of artesunate sulfadoxine pyrimethamine tablet?

In the pharmaceutical industry, the combination of Artesunate and Sulfadoxine-Pyrimethamine (AS+SP) is a powerful Artemisinin-based Combination Therapy (ACT). As a pharmacist, I characterize this fixed-dose combination (FDC) as a strategic multi-target treatment designed to clear parasites rapidly while providing a long-acting “chemical umbrella” to prevent the recurrence of infection.

Primary Clinical Uses

  • Treatment of Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum in areas where the parasite remains sensitive to the SP component.

  • Rapid Parasite Clearance: The Artesunate component ensures that the parasite load in the blood is reduced within hours, preventing the onset of severe malaria.

  • Prevention of Recrudescence: The long-acting Sulfadoxine and Pyrimethamine components remain in the bloodstream for weeks to kill any residual parasites.

  • Intermittent Preventive Treatment (IPT): In specific high-risk regions, this combination is sometimes utilized in pregnancy (IPTp) or for infants (IPTi) to reduce the burden of malaria.

  • Mechanism of Action

This combination employs a dual-mechanism approach to ensure parasitic death:

Artesunate (Fast-Acting): Generates reactive free radicals that damage the parasite’s proteins and membranes by reacting with the iron in the parasite’s food vacuole. It targets the asexual erythrocytic stages.

Sulfadoxine & Pyrimethamine (Long-Acting): These act as sequential inhibitors of folic acid synthesis. Sulfadoxine inhibits the enzyme dihydropteroate synthase, while Pyrimethamine inhibits dihydrofolate reductase. Since parasites must synthesize their own folates for DNA production, this blockade effectively halts their replication.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, AS+SP is a specialized product requiring high-tier regulatory compliance:

  • Stability Management: Artesunate is highly sensitive to moisture and heat. As a WHO-GMP manufacturer, we utilize Alu-Alu blister packaging and low-humidity manufacturing zones to protect the integrity of the Artesunate API during storage and transit.

  • Fixed-Dose Precision: We ensure that the ratio of Sulfadoxine to Pyrimethamine is precisely 20:1 (typically 500mg/25mg) to maintain the synergistic effect while minimizing potential side effects.

  • Global Export Niche: This combination is a staple for B2B distributors and government health tenders in sub-Saharan Africa and Southeast Asia. Our Mumbai hub is optimized for high-capacity production to meet international public health demands.

  • Regulatory Dossiers: We provide comprehensive CTD/eCTD documentation and stability data for Zone IVb to facilitate smooth registration in malaria-endemic international markets.

 

Posted on:

What is the use of Artemether and Lumefantrine tablets?

In the pharmaceutical industry, Artemether and Lumefantrine tablets (available in 20 mg/120 mg or 80 mg/480 mg strengths) represent the gold standard in Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this specific fixed-dose combination (FDC) as the most critical frontline defense against multi-drug resistant malaria.

Primary Clinical Uses

  • Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including infections acquired in chloroquine-resistant areas.

  • Pediatric and Adult Populations: Used widely across all age groups (standardized by weight) to ensure rapid clearance of parasites from the blood.

  • Stand-by Emergency Treatment: Often carried by travelers to malaria-endemic regions as a self-administered emergency treatment when medical facilities are unavailable.

Mechanism of Action

This combination provides a dual-phase attack on the malaria parasite:

Artemether: A semi-synthetic derivative of artemisinin. It acts rapidly to provide a fast “knockdown” of the parasite load by generating reactive free radicals that disrupt the parasite’s membrane and proteins.

Lumefantrine: A long-acting fluorene derivative. It acts more slowly but stays in the system longer to clear any residual parasites that survived the initial Artemether burst, preventing recrudescence (relapse).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Artemether-Lumefantrine is a high-precision product requiring stringent quality controls:

  • Fixed-Dose Combination (FDC) Stability: Artemether is a relatively unstable molecule sensitive to heat and moisture. As a WHO-GMP manufacturer, we utilize specialized granulation processes and Alu-Alu blister packaging to ensure stability, particularly for export to the high-heat environments of Africa and Southeast Asia.

  • Bioavailability: Lumefantrine has highly variable absorption. Our formulation includes specific excipients to ensure consistent absorption, especially when taken with fatty foods, which is a critical clinical requirement.

  • Global Health Tenders: This is a high-volume item for international NGOs, UNICEF, and the Global Fund. Our Mumbai-based facility is optimized to meet the massive demand for these tenders with full CTD/eCTD Dossier support.

  • Pediatric Dispersible Tablets: We also focus on dispersible formulations with pleasant flavoring to ensure easy administration and compliance in children, which is vital for reducing child mortality.

Artemether & Lumefantrine Tablets

Posted on:

What is the use of Artemether and Lumefantrine tablets?

In the pharmaceutical industry, Artemether and Lumefantrine tablets (available in 20 mg/120 mg or 80 mg/480 mg strengths) represent the gold standard in Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this specific fixed-dose combination (FDC) as the most critical frontline defense against multi-drug resistant malaria.

Primary Clinical Uses

  • Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including infections acquired in chloroquine-resistant areas.

  • Pediatric and Adult Populations: Used widely across all age groups (standardized by weight) to ensure rapid clearance of parasites from the blood.

  • Stand-by Emergency Treatment: Often carried by travelers to malaria-endemic regions as a self-administered emergency treatment when medical facilities are unavailable.

Mechanism of Action

This combination provides a dual-phase attack on the malaria parasite:

Artemether: A semi-synthetic derivative of artemisinin. It acts rapidly to provide a fast “knockdown” of the parasite load by generating reactive free radicals that disrupt the parasite’s membrane and proteins.

Lumefantrine: A long-acting fluorene derivative. It acts more slowly but stays in the system longer to clear any residual parasites that survived the initial Artemether burst, preventing recrudescence (relapse).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Artemether-Lumefantrine is a high-precision product requiring stringent quality controls:

  • Fixed-Dose Combination (FDC) Stability: Artemether is a relatively unstable molecule sensitive to heat and moisture. As a WHO-GMP manufacturer, we utilize specialized granulation processes and Alu-Alu blister packaging to ensure stability, particularly for export to the high-heat environments of Africa and Southeast Asia.

  • Bioavailability: Lumefantrine has highly variable absorption. Our formulation includes specific excipients to ensure consistent absorption, especially when taken with fatty foods, which is a critical clinical requirement.

  • Global Health Tenders: This is a high-volume item for international NGOs, UNICEF, and the Global Fund. Our Mumbai-based facility is optimized to meet the massive demand for these tenders with full CTD/eCTD Dossier support.

  • Pediatric Dispersible Tablets: We also focus on dispersible formulations with pleasant flavoring to ensure easy administration and compliance in children, which is vital for reducing child mortality.

Artemether & Lumefantrine Tablets

Posted on:

What is the use of Artemether and Lumefantrine tablets?

In the pharmaceutical industry, Artemether and Lumefantrine tablets (commonly in 20 mg/120 mg or 80 mg/480 mg strengths) represent the gold standard in Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this specific fixed-dose combination (FDC) as the most critical frontline defense against multi-drug resistant malaria.

Primary Clinical Uses

  • Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including infections acquired in chloroquine-resistant areas.

  • Pediatric and Adult Populations: Used widely across all age groups (standardized by weight) to ensure rapid clearance of parasites from the blood.

  • Stand-by Emergency Treatment: Often carried by travelers to malaria-endemic regions as a self-administered emergency treatment when medical facilities are unavailable.

Mechanism of Action

This combination provides a dual-phase attack on the malaria parasite:

Artemether: A semi-synthetic derivative of artemisinin. It acts rapidly to provide a fast “knockdown” of the parasite load by generating reactive free radicals that disrupt the parasite’s membrane and proteins.

Lumefantrine: A long-acting fluorene derivative. It acts more slowly but stays in the system longer to clear any residual parasites that survived the initial Artemether burst, preventing recrudescence (relapse).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Artemether-Lumefantrine is a high-precision product requiring stringent quality controls:

  • Fixed-Dose Combination (FDC) Stability: Artemether is a relatively unstable molecule sensitive to heat and moisture. As a WHO-GMP manufacturer, we utilize specialized granulation processes and Alu-Alu blister packaging to ensure stability, particularly for export to the high-heat environments of Africa and Southeast Asia.

  • Bioavailability: Lumefantrine has highly variable absorption. Our formulation includes specific excipients to ensure consistent absorption, especially when taken with fatty foods, which is a critical clinical requirement.

  • Global Health Tenders: This is a high-volume item for international NGOs, UNICEF, and the Global Fund. Our Mumbai-based facility is optimized to meet the massive demand for these tenders with full CTD/eCTD Dossier support.

  • Pediatric Dispersible Tablets: We also focus on dispersible formulations with pleasant flavoring to ensure easy administration and compliance in children, which is vital for reducing child mortality.

Artemether & Lumefantrine Tablets

Add to cart